Revelation Biosciences Inc. and Vanderbilt University Enter Exclusive Worldwide License Agreement
October 06 2022 - 7:00AM
Business Wire
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or
“Revelation”), a life sciences company that is focused on the
development of immunologic based therapies for the prevention and
treatment of disease, today announced an exclusive worldwide
license agreement with Vanderbilt University, Nashville TN, USA
(Vanderbilt) to develop and commercialize phosphorylated hexaacyl
disaccharide (PHAD), for treating or preventing infections.
The license covers potential applications such as prevention or
reduction of acquired infections including those resulting from
surgery, severe burns, and antibiotic resistance. According to the
most recent data published by the Center for Disease Control and
Prevention, approximately 687,000 cases of acquired infection in
acute care settings resulted in approximately 72,000 deaths.
Preclinical studies have shown that treatment with PHAD
significantly reduces the duration and severity of infection by
augmenting the innate immune response, a form of trained immunity.
The license grants Revelation the use of issued US patent
11,389,465.
“We are thrilled to have this license from Vanderbilt
University, an institution focused on improving the human condition
through pathbreaking discovery and innovation,” said James Rolke,
Chief Executive Officer of Revelation. “We are also very excited to
move the REVTx-100 program forward with this new license by
developing potentially lifesaving treatments for patients in need,
thanks in large part to work in the field of trained immunity.
Additionally, we believe the extensive preclinical data already
generated will allow us to rapidly bring this treatment to the
clinic.”
Revelation and Vanderbilt University will continue the
prosecution of additional patent applications, which will provide
Revelation the exclusive right to use these new technologies once
patents are granted.
About Revelation Biosciences Inc.
Revelation Biosciences, Inc. is a life sciences company focused
on the development of immunologic based therapies for the
prevention and treatment of disease. Revelation has multiple
product candidates in development that are based on the
well-established biology of PHAD and its effect on the innate
immune system. REVTx‑100 is being developed as a prevention and
treatment of infection. REVTx‑200 is being developed as an
intranasal immunomodulator adjunct to be used in combination with
an intramuscular vaccination for more complete immunity. REVTx‑300
is being developed as a potential therapy for the treatment of
acute and chronic organ disease including CKD, AKI, and NASH.
REVTx‑99b is being developed as a treatment for food allergies.
REVDx‑501 is being developed as a rapid diagnostic that can be used
to detect IP-10 as a surrogate biomarker for any type of
respiratory infection, without the need for specialized
instrumentation.
For more information on Revelation, please visit
www.RevBiosciences.com.
About Vanderbilt University
Vanderbilt University, located in Nashville, Tennessee, USA, is
a private research university offering a full range of
undergraduate, graduate, and professional degrees.
For more information, please visit www.vanderbilt.edu.
Forward-Looking Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These forward-looking statements are generally
identified by the words "anticipate", "believe", "expect",
"estimate", "plan", "outlook", and "project" and other similar
expressions. We caution investors that forward-looking statements
are based on management’s expectations and are only predictions or
statements of current expectations and involve known and unknown
risks, uncertainties and other factors that may cause actual
results to be materially different from those anticipated by the
forward-looking statements. Revelation cautions readers not to
place undue reliance on any such forward looking statements, which
speak only as of the date they were made. The following factors,
among others, could cause actual results to differ materially from
those described in these forward-looking statements: the ability of
Revelation to meet its financial and strategic goals, due to, among
other things, competition; the ability of Revelation to grow and
manage growth profitability and retain its key employees; the
possibility that the Revelation may be adversely affected by other
economic, business, and/or competitive factors; risks relating to
the successful development of Revelation’s product candidates; the
clinical utility of an increase in intranasal cytokine levels as a
biomarker of viral infections; the ability to successfully complete
planned clinical studies of its product candidates; the risk that
we may not fully enroll our clinical studies or enrollment will
take longer than expected; risks relating to the occurrence of
adverse safety events and/or unexpected concerns that may arise
from data or analysis from our clinical studies; changes in
applicable laws or regulations; expected initiation of the clinical
studies, the timing of clinical data; the outcome of the clinical
data, including whether the results of such study is positive or
whether it can be replicated; the outcome of data collected,
including whether the results of such data and/or correlation can
be replicated; the timing, costs, conduct and outcome of our other
clinical studies; the anticipated treatment of future clinical data
by the FDA, the EMA or other regulatory authorities, including
whether such data will be sufficient for approval; the success of
future development activities for its product candidates; potential
indications for which product candidates may be developed; the
potential impact that COVID‑19 may have on Revelation’s suppliers,
vendors, regulatory agencies, employees and the global economy as a
whole; the ability of Revelation to maintain the listing of its
securities on NASDAQ; investor sentiment relating to SPAC related
going public transactions; the expected duration over which
Revelation’s balances will fund its operations; and other risks and
uncertainties described herein, as well as those risks and
uncertainties discussed from time to time in other reports and
other public filings with the SEC by Revelation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221006005385/en/
Company Contacts Sandra Vedrick Vice President, Investor
Relations & Human Resources Revelation Biosciences Inc. Email:
svedrick@revbiosciences.com
and
Chester Zygmont, III Chief Financial Officer Revelation
Biosciences Inc. Email: czygmont@revbiosciences.com
Revelation Biosciences (NASDAQ:REVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revelation Biosciences (NASDAQ:REVB)
Historical Stock Chart
From Apr 2023 to Apr 2024